Chronic myeloid leukaemia and human immunodeficiency virus (HIV) infection

International Journal of Hematology

Volumn 95, Issue 5, 2012, Pages 556-563

  Webb, Michael J ^a   Barrett, Claire L ^b   Pretorius, Christel ^b   Van Jaarsveld, Magdalena F ^a   Louw, Vernon J ^a  

^a UNIVERSITY OF THE FREE STATE   (South Africa)

^b UNIVERSITY OF THE FREE STATE   (South Africa)

Author keywords

Chronic myeloid leukaemia; HIV; Treatment adherence

Indexed keywords

IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COMORBIDITY; CYTOGENETICS; DRESS SYNDROME; EDEMA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MALE; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; CYTOGENETIC ANALYSIS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84862841204     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1073-2     Document Type: Article

References (51)

1. Spano JP, Costagliola D, Katlama C, Mounier R, Oksenhendler E, Khayat D. AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol. 2008;26:4834-42.
2. Verneris MR, Tuel L, Seibel NL. Pediatric HIV infection and chronic myelogenous leukemia. Pediatr AIDS HIV Infect. 1995;6:292-4.
3. Schlaberg R, Fisher JG, Flamm MJ, Murty VV, Bhagat G, Alobeid B. Chronic myeloid leukemia and HIV-infection. Leuk Lymphoma. 2008;49:1155-60. (Pubitemid 351943262)
4. Mahon FX, Nabera CB, Pellegin JL, Cony-Makhoul P, Leng B, Bernard P, et al. Improving the cytogenetic response to interferon alpha by zidovudine (AZT) in an HIV-positive chronic myelogenous leukemia patient. Leuk Lymphoma. 1997;26:205-7. (Pubitemid 27351027)
5. De la Tribonniere X, Leberre R, Plantier I, Alfandari S, Beuscart S, Jouet JP, et al. Chronic myelogenous leukemia in an HIVinfected patient. Infection. 1998;26:194. (Pubitemid 28279261)
6. Tsimberidou AM, Medina J, Cortes J, Rios A, Bonnie G, Faderl S, et al. Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. Leuk Res. 2004;28:657-60. (Pubitemid 38543204)
7. O'Brien SG, Guilhot F, Goldman DM, et al. International Randomized Study of Interferon Versus STI571 (IRIS) 7-year followup: sustained survival, low rate of transformation and increased rate of major molecular response in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib. Blood. 2008;112:Abstract 186.
8. Sterne JA, Hernán MA, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;366:378-84. (Pubitemid 41073955)
9. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724-34.
10. Boma PO, Durosinmi MA, Adediran IA, Akinola NO, Salawu L. Clinical and prognostic features of Nigerians with chronic myeloid leukemia. Niger Postgrad Med J. 2006;13:47-52.
11. Mukiibi JM, Nyirenda CM, Paul B, Adewuyi JO, Mzula EL, Malata HN. Chronic myeloid leukemia in central Africans. East Afr Med J. 2003;80:470-5. (Pubitemid 41184965)
12. Liebowitz MR, Derman DP, Jacobson R, Stevens K, Katz J. Chronic myeloid leukaemia in South African blacks. S Afr Med J. 1976;50:2035-7.
13. Rohrbacher M, Berger U, Hochhaus A, Metzgeroth G, Adam K, Lahaye T, et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia. 2009;23:602-4.
14. Othieno-Abinya NA, Nyabola LO, Kiarie GW, Ndege R, Maina JM. Chronic myeloid leukemia at the Kenyatta National Hospital. Nairobi East Afr Med J. 2002;79:593-7. (Pubitemid 36597581)
15. Southern African HIV Clinicians Society. Guidelines: antiretroviral therapy in adults. http://www.sajhivmed.org.za/index.php/sajhivmed/article/ viewFile/68/34. Accessed 6 Sept 2011.
16. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63:789-99. (Pubitemid 14141296)
17. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998;90:850-8. (Pubitemid 28280552)
18. Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118: 686-92.
19. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-97. (Pubitemid 41127293)
20. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30. (Pubitemid 30432540)
21. Noens L, van Lierde MA, de Bock R, Verhoef G, Zachée P, Berneman Z, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401-11.
22. Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381-8.
23. Ganesan P, Sagar TG, Dubashi B, Rajendranath R, Kannan K, Cyriac S, et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol. 2011;86:471-4.
24. Cramer J. Identifying and improving compliance patterns. In: Cramer JA, Spilker B, editors. Patient compliance in medical practice and clinical trials. New York: Raven Press; 1991. p. 387-92.
25. Sewitch MJ, Abrahamowicz M, Barkun A, Bitton A, Wild GE, Cohen A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003;98:1535-44. (Pubitemid 36875345)
26. Baccarani M, Cortes J, Pane F, Niederwieser D, Sagglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041-51.
27. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-310. (Pubitemid 32804122)
28. Salami AK, Fadeyi A, Ogunmodede JA, Desalu O. Factors influencing adherence to antiretroviral medication in Ilorin, Nigeria. J Int Assoc Physicians AIDS Care. 2010;9:191-5.
29. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94:652-61. (Pubitemid 34552485)
30. Eliasson L, Clifford S, Barber N, Marin D. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011;35: 626-30.
31. Murphy RA, Sunpath H, Kuritzkes DR, Venter F, Gandhi RT. Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. J Infect Dis. 2007;196(Suppl 3):S449-56. (Pubitemid 351417238)
32. Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Druker BJ. Declining rates of adverse events (AEs), rare occurrence of serious AEs, and no unexpected long-term side effects at 5 years in patients with newly diagnosed chronic myeloid leukemia in chronic phase initially treated with imatinib in the international randomized study of interferon vs STI571 (IRIS). Blood. 2006; 108(Suppl):Abstract 2136.
33. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260-70.
34. Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, et al. Results of dasatinib therapy in patients with early chronicphase chronic myeloid leukemia. J Clin Oncol. 2010;28:398-404.
35. Marin D, Marktel S, Bua M, Szydlo RM, Franceschino A, Nathan I, et al. Prognostic factors for patients with chronic myeloid leukemia in chronic phase treated with imatinib mesylate after failure of interferon-alpha. Leukemia. 2003;17:1448-53. (Pubitemid 36986945)
36. Calenda V, Chermann JC. The effects of HIV on hematopoiesis. Eur J Haematol. 1992;48:181-6.
37. Miguez-Burbano MJ, Jackson J Jr, Hadrigan S. Thrombocytopenia in HIV disease: clinical relevance, physiopathology and management. Curr Med Chem Cardiovasc Hematol Agents. 2005;3:365-76. (Pubitemid 41264273)
38. Peltzer K. Utilization and practice of traditional/complementary/ alternative medicine (TM/CAM) in South Africa. Afr J Tradit Complement Altern Med. 2009;6:175-85.
39. ® (Imatinib) Prescribing Information. East Hanover (NJ): Novartis Pharmaceutical Company. www.pharma.us.novartis.com/product/pi/ pdf/gleevec-tabs.pdf. Accessed 11 June 2010.
40. Bolton AE, Peng B, Hubert M, Krebs-Brown A, Dapdeville R, Keller U, et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol. 2004;53:102-6. (Pubitemid 38186987)
41. Efavirenz: drug information. http://www.uptodate.com/contents/efavirenz- drug-information?source=search-result&search=efavi renz&selectedTitle= 1%7E92. Accessed 6 Sept 2011.
42. Phillips E, Mallal S. Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol. 2007;7:324-30. (Pubitemid 47052020)
43. Goldman J, Duval-Modeste AB, Lambert A, Contentin N, Courville P, Musette P, et al. Imatinib-induced DRESS (Article in French). Ann Dermatol Venereol. 2008;135:393-6.
44. Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010;28:424-30.
45. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109:3496-9. (Pubitemid 46572540)
46. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022-8.
47. Santachiara R, Maffei R, Martinelli S, Arcari A, Piacentini F, Trabacchi E, et al. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor. Haematologica. 2008;93:1252-5.
48. Cervetti G, Carulli G, Galimberti S, Azzarà A, Canmizzo E, Buda G, et al. Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia. Leuk Res. 2008;32:191-2. (Pubitemid 350100829)
49. Humlová Z, Klamová H, Janatková I, Sandová P, Sterzl I, Sobotková E, et al. Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment. Clin Dev Immunol. 2010;2010:137320.
50. Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res. 2008;14: 2484-91. (Pubitemid 351551084)
51. Chen J, Schmitt A, Chen B, Rojewski M, Rübeler V, Fei F, et al. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med. 2008;12:2107-18.